SITE MAP   |   CAREERS   |   CONTACT   |   
Partnered Programs




Zalicus is eligible to receive royalty and milestone revenue from Sanofi/Fovea Pharmaceuticals on the product candidate Prednisporin™/FOV1101, a topical ocular drug candidate containing low doses of the glucocorticoid, prednisolone acetate and the immunosuppressant cyclosporine A to treat inflammatory ocular diseases such as persistent allergic conjunctivitis.